TGFB1 and pancreatic adenocarcinoma: This mechanism is a key mediator of the effect of TGF‐β signaling in pathologies such as muscle weakness in bone metastases (Waning et al., 2015), epithelial‐mesenchymal transition in pancreatic adenocarcinoma (Hiraga et al., 2013), and tissue fibrosis (Jain et al., 2013).